Skip to Content
Market Update

Which Funds Got the Biggest Biogen Boost?

These funds had the largest holdings of the drugmaker's stock before it soared.

Mentioned: , , , , , ,

As Biogen shares surged on the news that the U.S. Food and Drug Administration approved Biogen's (BIIB) Aduhelm as a treatment for Alzheimer's disease, some mutual funds were in prime position to benefit from the stock's nearly 40% rally.

Biotechnology-focused strategies were the obvious winners thanks to heavy positions in Biogen. This was welcome news for biotech-heavy strategies, which have lagged amid the stock market’s rotation away from high-growth stocks toward value names.

Jakir Hossain does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.